hsa-miR-222

ncRNA information

ncRNA name

hsa-miR-222

Specific or universal ncRNAs

Universal ncRNAs

Class

MicroRNA

Biomarker

No

Biomarker application

Upstream regulatory factors

Not available

Downstream target

PTEN/Akt/FOXO1 signaling pathway

Cancer information

Cancer name

Breast Cancer

Cancer site

Breast

Treatment information

Treatment type

Chemotherapy

Drug

Adriamycin

Impact of wild-type ncRNA on chemotherapy resistance

Up

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.

Tissue resource

human breast cancer cell lines MCF-7

Experiment

qRT-PCR,Western blot


Institute

the Cell Bank of the Chinese Academy of Sciences

Country

China

Continent

Asia